-
COST OF HEALTHCARE IN PATIENTS NEWLY DIAGNOSED WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS
Feb 25, 2026, 14:42 PM -
IMPORTANCE OF ORAL DRUG PRODUCT CHARACTERISTICS TO PATIENTS AND IMPLICATIONS OF CHARACTERISTIC CHANGES FOR MISSED DOSES AND INFORMATION SEEKING
Feb 25, 2026, 14:42 PM -
ARE EVIDENCE REVIEW REQUIREMENTS SIMILAR ACROSS HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES? A CROSS-SECTIONAL STUDY OF NICE, CDA, IQWIG AND EU JCA
Feb 25, 2026, 14:42 PM -
REAL-WORLD INSIGHTS INTO OBESITY PATHWAYS, PRESCRIBING, PATIENT COMPLEXITY, AND CARE GAPS THROUGH PRIMARY CARE DATABASES
Feb 25, 2026, 14:42 PM -
CONTRACEPTION PREFERENCES OF WOMEN AND HEALTHCARE PROVIDERS: A DISCRETE CHOICE EXPERIMENT
Feb 25, 2026, 14:42 PM -
QUALITY ASSESSMENT IN A SYSTEMATIC LITERATURE REVIEW USING AN ARTIFICIAL INTELLIGENCE MODEL
Feb 25, 2026, 14:42 PM -
COST-EFFECTIVENESS OF OBICETRAPIB OR FIXED-DOSE COMBINATION AS AN ADJUNCT TO MAXIMALLY TOLERATED STATINS
Feb 25, 2026, 14:42 PM -
THE ECONOMIC COST OF PREVENTABLE BLINDNESS: PROJECTING THE SOCIOECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN CHILE (2017-2032)
Feb 25, 2026, 14:42 PM -
RETHINKING HEALTH ECONOMIC MODELS FOR OUTCOME-ALIGNED PAYMENTS: A FRAMEWORK FOR THE NEW 2026 CMS ACCESS MODEL
Feb 25, 2026, 14:42 PM -
CLINICAL AND ECONOMIC BURDEN IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES IN THE UNITED STATES
Feb 25, 2026, 14:42 PM -
ENABLING HEALTH TECHNOLOGY ASSESSMENT (HTA) TA READINESS THROUGH REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEWS (REAL-SLR): A BREAST CANCER (BCA) CASE STUDY
Feb 25, 2026, 14:42 PM -
COST SAVINGS OF AN AI-ENABLED DIGITAL TWIN PROGRAM IN PREDIABETES AND HEALTHY WEIGHT MANAGEMENT
Feb 25, 2026, 14:42 PM -
OPTIMIZING ENDPOINTS FOR CRSWNP BIOLOGIC TRIALS: REGULATORY, HTA, AND PATIENT-CENTERED EVIDENCE REQUIREMENTS
Feb 25, 2026, 14:42 PM -
REAL-WORLD UTILIZATION AND TREATMENT ADHERENCE OF BRAND AND GENERIC CYCLOSPORINE OPHTHALMIC EMULSION IN DRY EYE DISEASE
Feb 25, 2026, 14:42 PM -
TRENDS IN THE USE OF REAL-WORLD EVIDENCE IN PRESS RELEASES ISSUED BY THE TOP 15 PHARMACEUTICAL COMPANIES
Feb 25, 2026, 14:42 PM -
REAL-WORLD TREATMENT PATTERNS AND EFFICACY OF FIRST-LINE THERAPIES IN PATIENTS WITH MET EXON 14 SKIPPING-MUTATED NON-SMALL CELL LUNG CANCER
Feb 25, 2026, 14:42 PM -
DISMANTLING BARRIERS IN PATIENT-LED RESEARCH: UTILIZING AN AI-ENHANCED ACCESS-CENTERED RESEARCH MODEL TO EVALUATE THE INTEGRATION OF PATIENT-REPORTED OUTCOMES IN FDA ORPHAN DRUG APPROVALS
Feb 25, 2026, 14:42 PM -
NOVEL THERAPIES FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA POST BRUTON’S TYROSINE KINASE INHIBITOR: A TARGETED LITERATURE REVIEW
Feb 25, 2026, 14:42 PM -
COMPARATIVEEFFICACYANDSAFETYOF LONG-ACTING ANTIRETROVIRAL THERAPY IN HIV-1 MANAGEMENT: A NETWORK META-ANALYSIS
Feb 25, 2026, 14:42 PM -
GEOSPATIAL EQUITY AND ECONOMIC IMPLICATIONS OF HEALTH DEVELOPMENT OFFICES IN HUNGARY
Feb 25, 2026, 14:42 PM
